Samphire Neuroscience has raised $5M in Series A funding to expand its Nettle device targeting menstrual pain, led by Inventure VC and backed by Fortify Ventures.
Amount Raised
$5 Million
Round Type
Series A
LondonBiotechnologyHealth CareInvestors
Description
Samphire Neuroscience has raised $5 million in Series A funding to expand its Nettle brain device for menstrual symptoms. The round was led by Nordic venture capital firm Inventure VC, with participation from US-based Fortify Ventures. The funding will support continued commercial expansion and development of the company’s neurotechnology platform targeting women’s health conditions. Nettle offers a non-hormonal alternative for chronic menstrual issues, showing strong market demand since its recent European launch.
Quick answer
Samphire Neuroscience raised $5 Million in a Series A round, dated June 2, 2025. Investors: Fortify Ventures and Inventure VC. Samphire Neuroscience is based in London, England, United Kingdom.
- How much did Samphire Neuroscience raise?
- Samphire Neuroscience raised $5 Million in a Series A round on June 2, 2025.
- Who invested in Samphire Neuroscience?
- Fortify Ventures and Inventure VC are named as investors in this round.
- What does Samphire Neuroscience do?
- Samphire Neuroscience is a medtech startup focused on developing innovative neurotechnology solutions for women's health, with a particular emphasis on managing premenstrual syndrome (PMS) and menstrual pain.
- Where is Samphire Neuroscience based and how big is it?
- Samphire Neuroscience is based in London, England, United Kingdom.
- Who are the decision-makers at Samphire Neuroscience?
- Fundz holds 1 contact at Samphire Neuroscience. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology and Health Care around the same time
Companies in the same sectors as Samphire Neuroscience that raised within 45 days of this round, from Fundz verified event records.
- GenSight Biologics raised $580K (Seed) on July 17, 2025.
- OKYO Pharma raised $1.9M (Seed) on July 17, 2025.
- NKGen Biotech raised $2M (Seed) on July 17, 2025.
- Lumos Diagnostics raised $3.7M (Seed) on July 17, 2025.
- Little Journey raised $402K (Series A) on July 17, 2025.
- Zeus Hygia raised $2.5M (Series A) on July 16, 2025.
Who to call at Samphire Neuroscience, and when
A new round usually means Samphire Neuroscience is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Samphire Neuroscience raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Samphire Neuroscience, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Samphire Neuroscience. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Samphire Neuroscience raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansSamphire Neuroscience raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.